Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31249588 | 0.77 | CHRM2 (0.51) | CHRM2CHRM1CHRM3PREPEPHX2 | |
| SCHEMBL22338022 | 0.77 | CHRM2 (0.51) | CHRM2CHRM1CHRM3PREPEPHX2 | |
| SCHEMBL26922595 | 0.71 | CHRM2 (0.40) | CHRM2CHRM1CHRM3PREPEPHX2 | |
| SCHEMBL26923453 | 0.71 | CHRM2 (0.40) | CHRM2CHRM1CHRM3PREPEPHX2 | |
| SCHEMBL5037446 | 0.70 | CHRM2 (0.41) | CHRM2CHRM1CHRM3PREPHPGD | |
| SCHEMBL30968082 | 0.70 | CHRM2 (0.41) | CHRM2CHRM1CHRM3PREPHPGD | |
| SCHEMBL31080439 | 0.69 | CHRM2 (0.87) | CHRM2CHRM1CHRM3PREPHPGD | |
| SCHEMBL910981 | 0.69 | CHRM2 (0.87) | CHRM2CHRM1CHRM3PREPHPGD | |
| SCHEMBL910608 | 0.69 | CHRM2 (0.87) | CHRM2CHRM1CHRM3PREPHPGD | |
| SCHEMBL910610 | 0.69 | CHRM2 (0.87) | CHRM2CHRM1CHRM3PREPHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522597-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | CHRM2 4693/4885CHRM1 4664/4885CHRM3 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.